Psyence BioMed Forms Texas Ibogaine Research Corporation to Streamline U.S. Development
Event summary
- Psyence BioMed established Texas Ibogaine Research Corporation (TIRC) on September 14, 2026, to coordinate U.S. ibogaine development activities.
- TIRC is positioned to hold U.S. rights to pharmaceutical-grade ibogaine from PsyLabs, subject to definitive licensing arrangements.
- Jody Aufrichtig will serve as CEO of TIRC, with Dr. John Thorne appointed as project lead.
- TIRC will manage supply, manufacturing, regulatory, and potential clinical development activities through a single U.S. entity.
- The formation follows U.S. policy developments, including an Executive Order in April 2026 accelerating neuroplastogen research.
The big picture
The formation of TIRC aligns with growing U.S. momentum around regulated ibogaine research, following recent policy shifts and federal agency coordination. Psyence BioMed's move to centralize U.S. development activities under a dedicated entity reflects strategic positioning in the neuroplastogen therapeutics space, where regulatory clarity and clinical validation remain critical. The company's ability to leverage its existing resources and partnerships will be key to advancing ibogaine as a regulated therapeutic option.
What we're watching
- Regulatory Pathways
- Whether TIRC can secure necessary regulatory approvals and maintain compliance with U.S. controlled substance laws.
- Licensing Execution
- The pace at which definitive licensing arrangements with PsyLabs are completed and the terms agreed upon.
- Clinical Development
- How TIRC's coordination of manufacturing and clinical plans will position it for potential U.S. development programs.